Login / Signup

Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.

Kosuke TakemuraVishal NavaniMatthew S ErnstJ Connor WellsLuis MezaSumanta K PalJae-Lyun LeeHaoran LiNeeraj AgarwalAjjai S AlvaAaron R HansenNaveen S BasappaBernadett SzabadosThomas PowlesBen TranChristopher M HockingBenoit BeuselinckTakeshi YuasaToni K ChoueiriDaniel Y C Heng
Published in: The Journal of urology (2022)
The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncology-based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival.
Keyphrases
  • metastatic renal cell carcinoma
  • clinical trial
  • palliative care
  • adverse drug
  • randomized controlled trial
  • phase ii
  • free survival